Chicago (Reuters) - Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectation...
Original Article: Mixed results for Bristol/Nektar combination in cancer trial